Introduction: Addressing Therapeutic Oligo/Peptide Scale-Up, Purity Requirements, and Drug Discovery Bottlenecks
For pharmaceutical R&D directors, CMC managers, and biotechnology executives, oligonucleotides and peptides have emerged as powerful therapeutic modalities—antisense oligonucleotides (ASOs: Spinraza, Exondys 51), small interfering RNA (siRNA: Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio), CRISPR guide RNA (gRNA), and therapeutic peptides (semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), teriparatide (Forteo), leuprolide (Lupron)). However, translating these molecules from research tools (mg scale, <90% purity) to clinical candidates (gram to kg scale, >95–98% purity) requires specialized synthesis, purification, and analytical capabilities. Solid-phase oligonucleotide synthesis (phosphoramidite method) and solid-phase peptide synthesis (SPPS, Fmoc/t-Bu) enable custom design, but face challenges in yield, impurity control (truncated sequences, deletion sequences, stereochemistry), and manufacturing cost. As oligonucleotide therapeutics gain regulatory approvals (10+ marketed, 500+ clinical trials), peptide therapeutics expand (60+ marketed, 200+ clinical trials), and precision medicine drives demand for custom oligos/peptides, the synthesis market is experiencing robust growth. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Oligonucleotide and Peptide Synthesis – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oligonucleotide and Peptide Synthesis market, including market size, share, demand, industry development status, and forecasts for the next few years.
For outsourcing managers, drug discovery directors, and biotech investors, the core pain points include achieving high purity (>95–98%) and yield (>50–70%), controlling impurity profiles (N-1, N-2, deletion, epimerization, oxidation), and reducing manufacturing cost ($50k–500k per batch) for clinical and commercial supply. According to QYResearch, the global oligonucleotide and peptide synthesis market was valued at US$ 1,085 million in 2025 and is projected to reach US$ 1,633 million by 2032, growing at a CAGR of 6.1% .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097933/oligonucleotide-and-peptide-synthesis
Market Definition and Core Capabilities
Oligonucleotide and peptide synthesis refers to in vitro construction of nucleic acid fragments and peptide chains through chemical or enzymatic methods. Core capabilities:
- Oligonucleotide Synthesis (Solid-Phase Phosphoramidite Method): Automated synthesizers (1 nmol–100+ mmol scale). 3′ to 5′ synthesis cycle: detritylation, coupling (phosphoramidite + activator), capping, oxidation (I₂) or sulfurization (for phosphorothioate). DNA, RNA, 2′-O-methyl, 2′-fluoro, 2′-MOE, LNA, phosphorothioate (PS) modifications. Length: 10–200+ nt. Purity: >90–98% (crude), >98–99% (HPLC/PAGE purified). Used for ASOs, siRNA, aptamers, CpG, CRISPR gRNA, PCR primers, qPCR probes, FISH probes.
- Peptide Synthesis (Solid-Phase Peptide Synthesis, SPPS): Fmoc (9-fluorenylmethoxycarbonyl) or Boc (tert-butyloxycarbonyl) chemistry. Automated synthesizers (1 μmol–100+ mmol scale). C-terminal to N-terminal synthesis: deprotection, coupling (HBTU, HATU, PyBOP), cleavage, purification (HPLC). Length: 5–50+ amino acids. Purity: >70–85% (crude), >95–98% (HPLC purified). Modifications: acetylation, amidation, phosphorylation, glycosylation, PEGylation, cyclization, fluorescent labeling (FITC, TAMRA). Used for therapeutic peptides, peptide hormones, enzyme substrates, epitope mapping, vaccine antigens.
- Purification: Oligonucleotides – PAGE, HPLC (IEX, RP), SEC. Peptides – HPLC (RP, IEX), SEC.
- Analytical Testing: Mass spectrometry (ESI-MS, MALDI-TOF) for molecular weight confirmation. HPLC (IEX, RP) for purity, impurity profiling. Capillary electrophoresis (CE). Amino acid analysis (peptides). Endotoxin, bioburden (GMP-grade).
Market Segmentation by Type
- Oligonucleotide Synthesis (55–60% of revenue, fastest-growing at 6–7% CAGR): Therapeutic oligonucleotides (ASO, siRNA, aptamers, CpG, gRNA) – higher value, longer lengths (20–200 nt), complex modifications (PS, 2′-OMe, 2′-F, 2′-MOE, LNA). GMP-grade for clinical trials and commercial products. Research-grade oligos for PCR, qPCR, sequencing, FISH, CRISPR. Driven by oligonucleotide therapeutic approvals and clinical pipelines.
- Peptide Synthesis (40–45% of revenue, stable at 5–6% CAGR): Therapeutic peptides (semaglutide, liraglutide, teriparatide, leuprolide), research peptides (enzyme substrates, epitope mapping, vaccine antigens), and custom peptide libraries. Mature market, but growing with GLP-1 agonist demand (semaglutide – Ozempic/Wegovy). SPPS dominates; liquid-phase synthesis for large-scale (kg) manufacturing.
Market Segmentation by Application
- Biotech Company (65–70% of revenue, largest segment): Oligonucleotide therapeutics developers (Ionis, Alnylam, Sarepta, Biogen, Moderna, CRISPR Therapeutics). Peptide therapeutics developers (Novo Nordisk, Eli Lilly, Pfizer, Takeda, Amgen). CDMO outsourcing due to lack of in-house GMP synthesis capacity, high capital investment ($10–50M for GMP suite), and regulatory expertise. Research-grade oligos/peptides for drug discovery (HTS, hit-to-lead, lead optimization).
- Academic Scientific Research Institution (30–35% of revenue, fastest-growing at 6–7% CAGR): University labs, research institutes, non-profit organizations. Custom oligos/peptides for basic research (gene expression, protein structure-function, molecular interactions, biomarker discovery). Smaller scale (1 nmol–10 μmol), higher cost per unit ($10–1,000 per oligo/peptide). Growing demand for CRISPR gRNA, siRNA, peptide arrays.
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Scale-up from research to GMP (1 μmol to 100+ mmol for oligos; 1 μmol to 100+ mmol for peptides) requires validated synthesizers, optimized coupling efficiency (>99% per cycle for oligos; >99% per coupling for peptides), and impurity control. Impurity levels increase exponentially with length; length >50 nt (oligos) or >30 amino acids (peptides) has lower yield (<50%) and higher impurity levels. Phosphorothioate (PS) stereochemistry for ASOs requires control of Rp/Sp diastereomers (affects nuclease resistance, protein binding, potency). Stereo-defined PS synthesis (chiral amidites) under development but not yet widely adopted for GMP. Peptide epimerization and aggregation during SPPS (especially for long peptides, >30 aa) reduces yield and purity. Optimized coupling conditions (low temperature, extended reaction time, pseudoproline dipeptides) mitigate epimerization. Analytical characterization for modified oligos (multiple chiral centers, isobaric impurities) and peptides (deamidation, oxidation, aggregation) requires advanced methods (LC-MS/MS, 2D-LC, ion mobility). Reference standards for each impurity challenging.
独家观察: GLP-1 Agonist Peptides (Semaglutide, Liraglutide) Driving Peptide Synthesis Demand
An original observation from this analysis is the double-digit growth (10–12% CAGR) of large-scale peptide synthesis for GLP-1 receptor agonists (semaglutide – Ozempic/Wegovy, liraglutide – Victoza/Saxenda, tirzepatide – Mounjaro/Zepbound) . Semaglutide (31 amino acids) requires multi-kg quantities (>1,000 kg/year) for commercial supply, driving CDMO capacity expansion (Bachem, PolyPeptide, CordenPharma, Lonza). Peptide synthesis scale-up from research (1–100 mg) to commercial (>100 kg) requires process optimization (solid-phase vs. liquid-phase), purification (HPLC), and analytical control (impurity profiling). GLP-1 agonist market projected >$100B by 2030, sustaining peptide synthesis demand. Additionally, CRISPR guide RNA (gRNA) for ex vivo gene editing (CAR-T, TCR-T, iPSC) is an emerging application (10–12% CAGR). GMP gRNA (100–200 nt, chemically modified) required for IND-enabling studies and clinical trials. High purity (>95%), long sequence length, and complex modifications challenge current GMP synthesis capacity.
Strategic Outlook for Industry Stakeholders
For CEOs, product line managers, and biopharma investors, the oligonucleotide and peptide synthesis market represents a steady-growth (6.1% CAGR), high-margin CDMO opportunity anchored by oligonucleotide therapeutic approvals (ASO, siRNA), GLP-1 agonist peptides, and CRISPR gene editing pipelines. Key strategies include:
- Investment in large-scale GMP synthesis capacity (100–500+ mmol for oligos; 100+ mmol for peptides) for commercial oligonucleotide and peptide therapeutics.
- Development of modified oligonucleotide synthesis expertise (2′-MOE, LNA, 2′-fluoro, phosphorothioate stereochemistry) for therapeutic ASOs and siRNAs.
- Expansion into CRISPR guide RNA (gRNA) GMP production (100–200 nt, high purity) for ex vivo gene editing (CAR-T, TCR-T, iPSC, HSC) and in vivo delivery.
- Geographic expansion into Asia-Pacific (China, South Korea, Japan) for oligonucleotide/peptide CDMO outsourcing and North America/Europe for commercial supply.
Companies that successfully combine large-scale synthesis, modified oligonucleotide/peptide chemistry, and regulatory expertise (FDA, EMA, PMDA, NMPA) will capture share in a $1.6 billion market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
